CLINICAL TRIALS PROFILE FOR CIPROFLOXACIN

505(b)(2) Clinical Trials for CIPROFLOXACIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01168895 ↗	Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder	Completed	Bayer	Phase 1	2010-07-01	The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75 mg dose will be administered for the first time using a new high dose strength (i.e. one capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. Safety investigations will focus on local tolerability in the lung and evaluate whether the patient can inhale the higher amount of powder compared to the lower dose strength. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. Results from this study will be used to decide whether the new dose strength is suitable for larger clinical trials planned for the COPD patients population.

All Clinical Trials for CIPROFLOXACIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000641 ↗	A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per 03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is the most common systemic bacterial infection complicating AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely poor, particularly when it follows other opportunistic infections or is associated with anemia. Test tube studies and clinical data indicate that the best treatment program may include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because it must be administered parenterally (by injection or intravenously).
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Eastern Cooperative Oncology Group	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Gary Morrow	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00003407 ↗	Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia	Unknown status	National Cancer Institute (NCI)	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia.
NCT00003407 ↗	Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia	Unknown status	Rush University Medical Center	Phase 2	1998-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia.

Clinical Trial Conditions for CIPROFLOXACIN

Condition Name

Condition Name for CIPROFLOXACIN
Intervention	Trials
Urinary Tract Infections	17
Healthy	12
Infection	8
Pouchitis	7

Condition MeSH

Condition MeSH for CIPROFLOXACIN
Intervention	Trials
Infections	47
Infection	39
Communicable Diseases	36
Urinary Tract Infections	34

Clinical Trial Locations for CIPROFLOXACIN

Trials by Country

Trials by Country for CIPROFLOXACIN
Location	Trials
United States	509
Germany	44
Spain	43
United Kingdom	43
Canada	39

Trials by US State

Trials by US State for CIPROFLOXACIN
Location	Trials
Texas	33
California	32
Florida	27
North Carolina	24
Ohio	23

Clinical Trial Progress for CIPROFLOXACIN

Clinical Trial Phase

Clinical Trial Phase for CIPROFLOXACIN
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	9

Clinical Trial Status

Clinical Trial Status for CIPROFLOXACIN
Clinical Trial Phase	Trials
Completed	174
Recruiting	46
Not yet recruiting	30

Clinical Trial Sponsors for CIPROFLOXACIN

Sponsor Name

Sponsor Name for CIPROFLOXACIN
Sponsor	Trials
Bayer	23
National Institute of Allergy and Infectious Diseases (NIAID)	8
PriCara, Unit of Ortho-McNeil, Inc.	6

Sponsor Type

Sponsor Type for CIPROFLOXACIN
Sponsor	Trials
Other	388
Industry	146
NIH	20

Clinical Trials Update, Market Analysis, and Forecast for Ciprofloxacin (Oral, IV, and Ophthalmic/OTIC Formulations)

Last updated: July 23, 2026

What clinical trial updates exist for ciprofloxacin in 2024–2026?

A CIPROFLOXACIN development picture in 2024–2026 is best framed by three buckets: new antibacterial efficacy work (including drug-combination trials), label-expansion programs (where permitted by endpoints), and safety-focused studies tied to safety-label management in fluoroquinolones.

Which ciprofloxacin indications are seeing active trials?

Across public trial registries, ciprofloxacin trials cluster around:

• Complicated urinary tract infection (cUTI) and/or acute pyelonephritis (AP) use cases where enrollment targets include resistant organisms.
• Skin and soft tissue infection (SSTI) subsets when fluoroquinolones are compared to beta-lactam regimens.
• Otitis externa and other ophthalmic/otic indications for formulation-specific endpoints (retention time, corneal penetration, microbiologic eradication).
• Pediatric studies and pharmacokinetic (PK) bridging studies where regulators require age-appropriate exposure characterization.

What endpoints dominate current ciprofloxacin studies?

Most late-stage and registration-oriented studies use:

• Microbiologic eradication at test-of-cure (TOC).
• Composite clinical response (often early clinical response + TOC).
• Safety endpoints that capture class-relevant risks (tendon injury signals, QT effects surveillance, CNS adverse events), consistent with fluoroquinolone labeling.

How do trials handle antimicrobial resistance?

Trials increasingly stratify or enrich by:

• Baseline pathogen MIC categories for fluoroquinolones.
• Separate arms or post-hoc subgroup analyses for Gram-negative Enterobacterales including fluoroquinolone-resistant strains.

(No complete registry cross-check is included here because you requested a “clinical trials update” but did not provide any scope such as geography, route, or sponsor set. A fully accurate update requires drug-formulation and registry filtering that is not specified.)

---

How big is the ciprofloxacin market today, and what segments drive revenue?

Ciprofloxacin is a mature fluoroquinolone with a large global baseline from generics, with revenue concentrated in:

• Oral tablets and extended oral regimens
• IV use for inpatient complicated infections
• Ophthalmic solutions/ointments and otic suspensions (where formulation differentiation matters more than molecule-level IP)

What segment mix matters most commercially?

• Hospital/inpatient share: IV and oral bridging for acute Gram-negative infections.
• Community share: oral use for uncomplicated-to-complicated UTI categories in settings with antibiotic stewardship programs.
• Ophthalmic/otic share: higher formulation sensitivity, lower direct competition from systemically interchangeable generics.

What pricing pressure shapes the market?

• Patent expiry-driven generic penetration compresses prices in most major markets.
• Procurement contracts favor lowest-cost equivalents unless formulation-specific switching is restricted.

---

When does ciprofloxacin lose exclusivity for key brands by route and jurisdiction?

For ciprofloxacin as an active ingredient, exclusivity depends on:

• Brand-specific patents (formulation, polymorph, crystallinity, dosing regimen)
• Country-specific SPCs and pediatric extensions (where applicable)
• Orange Book-listed formulation patents (US) for certain branded products, not for the drug substance broadly

What is the practical exclusivity status for ciprofloxacin as a molecule?

• In the US and EU, ciprofloxacin has been widely generic for years for systemic indications.
• Any remaining exclusivity is typically formulation- or method-of-use-specific and product-specific rather than molecule-wide.

(A precise exclusivity timeline for “ciprofloxacin” requires selecting a specific branded product, dosage form, and jurisdiction.)

---

What patents protect ciprofloxacin, and how many IP families typically exist?

Ciprofloxacin patenting is dominated by:

• Formulation patents (e.g., sustained-release compositions, specific excipient systems)
• Manufacturing/process patents
• Solid-state variants (where claimed)
• Method-of-use patents tied to dosing regimens or specific indications (less common for older assets)

How many IP families cover ciprofloxacin in practice?

Market reality is that:

• Substance-level patents are long expired for essentially all major markets.
• Active patent families typically map to specific finished products, not the base compound.

---

What Orange Book status applies to ciprofloxacin products in the US?

The US Orange Book status for “ciprofloxacin” is product-specific:

• Multiple approved products exist across strengths and dosage forms.
• Orange Book lists patents by NDA and supplement, with some patents covering formulation or use.

A fully accurate Orange Book mapping requires the exact NDA/strength/dosage form. A molecule-level summary would be incomplete.

---

What generic entry risks exist for ciprofloxacin based on Paragraph IV challenges?

For mature fluoroquinolones with broad generic availability:

• Paragraph IV challenges are less relevant for the molecule broadly and more relevant only for brand-specific formulation patents that remain listed.
• For systemically interchangeable generics, entry risk is primarily governed by whether any Orange Book-listed patents remain unexpired for the specific referenced product.

---

How does ciprofloxacin compare with levofloxacin and other fluoroquinolones on market and prescribing?

In markets where fluoroquinolones are used for similar indications:

• Ciprofloxacin often holds a cost and spectrum advantage for Gram-negative coverage.
• Levofloxacin sometimes captures market share in respiratory-oriented use cases, depending on local stewardship rules and guideline preferences.

What drives switch behavior between fluoroquinolones?

• Formulary placement and hospital procurement pricing
• Safety communications and internal risk management protocols
• Resistance patterns at the hospital and region level
• Route convenience (oral bioavailability, IV availability)

---

What FDA regulatory status applies to ciprofloxacin today?

Ciprofloxacin has multiple approved indications and routes; regulatory status differs by dosage form:

• Systemic: tablets and IV for specific UTI/AP and other indications per approved labeling
• Ophthalmic/otic: solution/suspension for bacterial conjunctivitis and otitis externa categories per product labeling

Regulatory management in the US also reflects fluoroquinolone class labeling updates addressing serious adverse events risks.

---

What is the outlook for ciprofloxacin clinical demand: 2026–2030?

Market demand is likely to track:

• Persistent need for oral and IV Gram-negative coverage
• Ongoing competition from other antibiotic classes, including cephalosporins, carbapenems (for severe resistant infections), and newer agents in some resistant indications
• Continued antibiotic stewardship affecting fluoroquinolone use, especially outpatient fluoroquinolone restrictions in certain geographies

A realistic projection assumes:

• Limited unit growth for systemic use (low elasticity, mature usage)
• Growth tied to population and hospital admissions, tempered by stewardship and resistance-specific selection
• Incremental share shifts toward the lowest-cost generics and away from higher-cost formulations

---

Market forecast: revenue and growth projection for ciprofloxacin (framework)

A defensible forecast requires:

• Baseline revenue by region and route (oral vs IV vs ophthalmic/otic)
• Generic price erosion curves and procurement effects
• Share shifts due to guideline adoption and stewardship controls
• Capacity expansions and competitive entry waves

Because the prompt does not specify which geography, route, or payer setting, only a decision-grade framework can be stated:

Forecast drivers (most material)

1. Generic price pressure from continued approvals and tender competition
2. Stewardship policies restricting empiric fluoroquinolone use in select settings
3. Resistance patterns influencing fluoroquinolone utility in Gram-negative infections
4. Formulation differentiation for ophthalmic and otic products with less direct substitution

Forecast baseline direction

• Mature systemic: low-to-mid single digit CAGR typically constrained by pricing erosion
• Ophthalmic/otic: potentially steadier unit demand with route-specific labeling and switching dynamics

---

What commercial risks could change ciprofloxacin’s forecast?

Key downside risks:

• Additional fluoroquinolone safety label tightening that reduces use
• Loss of formulary positions in major hospital systems
• Structural pricing declines due to intensified generic competition
• Substitution by newer agents for resistant Gram-negative infections, reducing fluoroquinolone demand in high-acuity cohorts

Key upside risks:

• New evidence supporting specific regimen efficacy in resistant settings leading to guideline re-uptake
• Availability of optimized formulations that improve adherence or reduce dosing frequency and increase uptake

---

Key Takeaways

• Ciprofloxacin is a mature fluoroquinolone with market dynamics driven primarily by generic pricing, stewardship, and route-specific differentiation (especially ophthalmic/otic).
• “Clinical trials update” activity largely centers on ongoing efficacy/safety endpoints, resistance-stratified enrollment, and formulation or PK bridging rather than novel molecule development.
• Exclusivity and patent risk are product-specific, typically tied to formulation or method-of-use patents rather than the ciprofloxacin drug substance itself.
• Market projection direction is constrained: systemic revenue growth is usually limited by price erosion; ophthalmic/otic can behave more steadily depending on product switching.

---

FAQs

1. What are the most common ciprofloxacin clinical endpoints used in registration trials?
2. Which ciprofloxacin dosage forms face the most generic substitution pressure?
3. How do antibiotic stewardship rules affect outpatient ciprofloxacin prescribing by region?
4. What are the main fluoroquinolone safety label issues that impact ciprofloxacin utilization?
5. How do resistance patterns change ciprofloxacin selection for complicated UTIs and pyelonephritis?

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. U.S. Food and Drug Administration. Drug Safety Communications on fluoroquinolones. (Accessed 2026).
3. ClinicalTrials.gov. Ciprofloxacin trials search results. (Accessed 2026).